GRI Bio SEC Filings

GRI Bio, Inc. reporting person David Leslie Szekeres received a stock option award totaling 39,897 shares exercisable at $1.93. The options were granted and reported with a transaction date of 09/18/2025, become exercisable immediately for 29,293 shares and for the remaining 9,974 shares vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of grant. The options expire on 09/18/2035 and are reported as direct beneficial ownership, leaving 39,897 shares underlying the option beneficially owned after the transaction.

GRI Bio, Inc. (GRI) director David Charles Baker was granted a stock option on 09/18/2025 to buy 23,605 shares of common stock at a $1.93 exercise price. The option becomes exercisable on 09/18/2025 and expires on 09/18/2035. Of the total, 17,621 options vested immediately on the grant date and 5,984 options will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The Form 4 was filed by a single reporting person and signed via attorney-in-fact on 09/22/2025.

GRI Bio insider option grant: Director Camilla V. Simpson was granted a stock option on 09/18/2025 to buy 23,605 shares of GRI Bio common stock at a $1.93 exercise price. Of the option, 17,621 shares vested immediately on the grant date and 5,984 shares will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The option expires on 09/18/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/22/2025.

GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.

GRI Bio director Roelof Rongen reported a stock option grant that became partially vested on 09/18/2025. The filing shows options to purchase 23,605 shares of common stock at an exercise price of $1.93 per share, exercisable through 09/18/2035. Following the grant, Mr. Rongen beneficially owns 23,605 option shares directly. Of those options, 17,621 vested immediately on the grant date and 5,984 will vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of the grant date.

The Form 4 was filed as a single reporting person filing and bears a signature dated 09/22/2025 by an attorney-in-fact.

GRI Bio, Inc. (GRI) reporting person Walter Marc Hertz, identified as Director and Chief Executive Officer, was granted a stock option award on 09/18/2025 covering 103,067 shares with an exercise price of $1.93 per share. The award is exercisable through 09/18/2035. Under the grant, 76,469 options vested in full on the grant date and the remaining 26,598 options vest in 12 substantially equal quarterly installments, completing on the third anniversary of the grant. The Form 4 was signed by an attorney-in-fact on 09/22/2025. The filing shows direct beneficial ownership of the options and does not include additional cash compensation or other transaction types.

Walter Marc Hertz, identified as Chief Executive Officer and a director of GRI Bio, Inc. (GRI), reported on Form 4 a transaction dated 08/26/2025 involving stock options. He acquired 26,688 shares of common stock by exercising options with an exercise price of $1.41 per share. Of the options, 17,828 vested in full on the grant date and 8,860 will vest in 12 substantially equal quarterly installments, with the option fully vested on the third anniversary of the grant date. Following the transaction, Mr. Hertz beneficially owns 26,688 shares directly. The filing is signed by an attorney-in-fact, Leanne Kelly.

David Leslie Szekeres, a director of GRI Bio, Inc. (GRI), reported receipt of a stock option award covering 10,276 shares with an exercise price of $1.41 per share. The option was granted on 08/26/2025, has an expiration date in 2035, and 6,933 of the option shares vested immediately while the remaining 3,343 shares vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. Following the grant, the reporting person beneficially owns 10,276 option shares on a direct basis.

GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share. Of the total, 4,044 options vested immediately on the grant date; the remaining 1,950 options vest in four substantially equal quarterly installments and will be fully vested on the one-year anniversary of the grant. The options expire on 08/26/2035. Following the grant, Mr. Baker directly beneficially owns 5,994 underlying shares from the option award.